Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no visible changes to the study content or page layout were detected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T02:22:12.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    A consolidated Locations section now lists California, Illinois, Indiana, and Virginia, replacing the former separate California Locations, Illinois Locations, Indiana Locations, and Virginia Locations subsections; the HHS Vulnerability Disclosure link was removed.
    Difference
    0.5%
    Check dated 2025-12-23T10:14:42.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    Minor site-wide update applied: Revision v3.3.2 replaces v3.3.1; no changes to the study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T17:52:37.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page shows a new Revision: v3.3.1 and removal of Revision: v3.2.0, indicating a minor backend or metadata update without changing the trial details presented. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-11-24T14:45:40.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The page removed a general government funding status notice that previously appeared at the top, leaving the study details unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-17T06:56:37.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    The page content remains unchanged: the study overview, design, inclusion/exclusion criteria, and outcomes are as previously presented.
    Difference
    0.4%
    Check dated 2025-11-03T01:20:56.000Z thumbnail image

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.